认识Marc H. Hedrick时他还是UCLA的整形外科医生,但是他所引起人注意的是对脂肪干细胞的研究,发表了不少文章.组织工程和干细胞在21世纪初时是热得不能再热了,我博士的研究内容主要就是胚胎干细胞,那时人人都觉得干细胞马上就要用到临床,可以治病了.于是Hedrick就成立了一个公司,叫Cytori Therapeutics’ ,可是公司是要出产品,是要赢利的啊,而Marc H. Hedrick的研究还仅是基础的,比如怎样从抽脂的脂肪中提出干细胞,脂肪干细胞在什么样的诱导下可以变成想要的细胞等等.于是他们的公司经营的方向就不仅仅是脂肪干细胞了,更进了一层,希望以干细胞治疗心脏病,椎间盘疾病及胃肠方面的问题.目前好象是出了一套脂肪干细胞提取和保存的系统.看下公司介绍:

昨天把他在UCLA做住院医生时的照片拍了下来,UCLA的整形科医生都很英俊,魅力实足.有空应该去拜访一下他和他的公司,这是一个整形外科医生的不同道路.

另外洽谈一下合作事宜,希望在南京也能开展脂肪干细胞的工作,抽了脂,还能提取,储存,再用于疾病治疗和抗衰老.

Marc H. Hedrick, M.D.
President
Dr. Marc H. Hedrick was appointed President in May 2004. Dr. Hedrick joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, Dr. Hedrick co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. Dr. Hedrick is a plastic surgeon, is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, Dr. Hedrick directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick obtained his M.D. from the University of Texas Southwestern Medical School, Dallas.

还收到他的消息是:他又获得了工商管理硕士(M.B.A. from UCLA Anderson School of Management.)还有他去年的年薪是37万多.在美国可能和一个好的整形外科医生相当.网络的力量就是使人快没有隐私了.哈哈.

Cash Compensation(FYDecember 2007) Salary $372,312

Cytori Therapeutics’ (NASDAQ: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients’ adult stem and regenerative cells.

To reach its goal, Cytori has developed its innovative Celution™ System to separate and concentrate a patient’s own adult stem and regenerative cells from adipose (fat) tissue to be delivered back to the patient during the same surgical procedure.

The Celution™ System will be introduced in 2008 in Europe into the plastic and reconstructive surgery market and launched in Japan for cryopreserving a patient’s own stem and regenerative cells. Clinical trials are ongoing or planned in cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs.

点击放大图片

  Tag: 脐带血| 脐带| 脐带干细胞| 脂肪干细胞| 胎盘干细胞| 羊胎水| 抗衰老|